Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental cancer combo shows promise but trial halted early

NCT ID NCT04972110

Disease control Sponsor: Repare Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug, RP-3500 (camonsertib), combined with existing PARP inhibitors (niraparib or olaparib) in 156 adults with advanced solid tumors that have specific genetic markers. The goal was to find safe doses and see if the combination could shrink tumors. However, the study was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RP-3500 (camonsertib) combined with niraparib or olaparib
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced cancers that have specific genetic changes and have stopped responding to standard therapies.
What could go wrong
The trial was terminated early, so results are limited. The combination may cause significant side effects, and it is unclear if it will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

156 people

The number who actually took part.

Started

Jul 2021

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female and ≥18 years-of-age at the time of signature of the informed consent * Confirmed advanced solid tumors resistant or refractory to standard treatment * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. * Evaluable disease as per RECIST v1.1 * Next generation sequencing (NGS) report obtained in CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarkers. * Submission of available tumor tissue or willingness to have a biopsy performed if safe and feasible * Acceptable hematologic and organ function at screening * Negative pregnancy test for women of childbearing potential at Screening and prior to first study drug. * Ability to swallow and retain oral medications. Exclusion Criteria: * Prior therapy with an ATR or DNA-dependent protein kinase (DNA-PK) inhibitor. * Chemotherapy, small molecule anticancer or biologic anticancer therapy given within 10 days or 5 half-lives (whichever is longer), prior to first dose of study drug. * Use of radiotherapy (except for palliative reasons) within 7 days prior to first dose of study drug. * History or current condition, therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment. * No other anticancer therapy is to be permitted while the patient is receiving study treatment. * Major surgery ≤28 days or minor surgical procedures ≤7 days prior to first study treatment dose. * Uncontrolled, symptomatic brain metastases. * Uncontrolled high blood pressure * History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) diagnosis * Presence of other known active invasive cancers. * Pregnant or breastfeeding women. * Psychological, familial, sociological, or geographical conditions that do not permit compliance with the study protocol and/or follow-up procedures outlined in the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumor, adult

Contacts and locations

Locations

  • Participating Site # 1001

    Houston, Texas, 77030, United States

  • Participating Site # 1008

    New York, New York, 10032, United States

  • Participating Site # 1013

    Salt Lake City, Utah, 84112, United States

  • Participating Site # 1016

    Rochester, Minnesota, 55905, United States

  • Participating Site #1009

    Baltimore, Maryland, 21205, United States

  • Participating Site #1012

    New Haven, Connecticut, 06511, United States

  • Participating Site #1015

    Ann Arbor, Michigan, 48109, United States

  • Participating Site #1017

    Jacksonville, Florida, 32224, United States

  • Participating Site #1018

    Phoenix, Arizona, 97401, United States

  • Participating Site #1025

    San Francisco, California, 94158, United States

  • Participating Site #1026

    New York, New York, 10029, United States

  • Participating Site #1028

    Aurora, Colorado, 80012, United States

  • Participating Site #1029

    Eugene, Oregon, 97401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.